Collegium Pharmaceutical
COLL
163 hedge funds and large institutions have $900M invested in Collegium Pharmaceutical in 2021 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 50 increasing their positions, 54 reducing their positions, and 13 closing their positions.
192% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 13
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
69% more call options, than puts
Call options by funds: $2.42M | Put options by funds: $1.43M
21% more capital invested
Capital invested by funds: $745M → $900M (+$156M)
18% more funds holding
Funds holding: 138 → 163 (+25)
1.85% more ownership
Funds ownership: 107.49% → 109.35% (+1.9%)
7% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 54
Top Buyers
| 1 |
BlackRock
New York
|
+$72.4M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$11.7M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.8M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$10.5M |
| 5 |
Principal Financial Group
Des Moines,
Iowa
|
+$7.93M |
Top Sellers
| 1 |
PA
Perceptive Advisors
New York
|
-$25.7M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$25.1M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$24M |
| 4 |
FM
Frazier Management
Seattle,
Washington
|
-$18.9M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$11.9M |
COLL Hedge Fund Activity: Q1 2021 in Review
163 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q1 2021, worth a combined $900M — up 21% from $745M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new COLL positions and 13 closed out — a net gain of 25 holders — while 50 added to existing stakes and 54 trimmed.
The largest buyer was BlackRock, adding an estimated $72.4M. The largest seller was Perceptive Advisors, cutting an estimated $25.7M.
- 163 institutional investors held Collegium Pharmaceutical (COLL) as of Q1 2021, up from 138 in Q4 2020.
- Funds reported $900M of Collegium Pharmaceutical stock for Q1 2021, up 21% quarter-over-quarter.
- 38 funds opened new Collegium Pharmaceutical positions in Q1 2021 and 13 closed out, a net change of +25 holders.
- The largest Collegium Pharmaceutical buyer in Q1 2021 was BlackRock, an estimated $72.4M added.
- The largest Collegium Pharmaceutical seller in Q1 2021 was Perceptive Advisors, an estimated $25.7M sold.
Based on aggregated 13F filings for Q1 2021.